Beacon Biosignals

• ·Beacon Biosignals’s last known valuation is $334.0M (Oct 2025).
• ·It has raised $126.9M across 2 recorded rounds; the latest was Later Stage VC ($103.3M) in Oct 2025.
• ·Notable investors include Alumni Ventures, General Catalyst, GV, Samsung NEXT Ventures, Inovia Capital — 20 tracked in total.
• ·2 investment vehicles were formed to buy Beacon Biosignals shares in the last 12 months, reporting $974K sold to 39 investors, per SEC Form D filings.
• ·Beacon Biosignals has filed 2 Form Ds with the SEC since 2021, most recently Apr 2026 ($103.3M sold to 43 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 2 investment vehicles were formed to buy Beacon Biosignals shares, reporting $974K sold to 39 investors across 2 sponsors. Most recent filing Feb 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of an artificial intelligence-based neurotechnology platform designed for accelerating the clinical development of therapeutics targeting brain health. The company's platform utilizes FDA-cleared headband devices to collect high-fidelity sleep electroencephalogram and applies AI algorithms to characterize brain function, detect novel biomarkers, enabling clinical research teams to optimize treatment impact.

Sector

Healthcare

HQ

Boston, MA, United States

Founded

2019

Employees

121

Website

beacon.bio/

Ownership

Privately Held (backing)